XtalPi Holdings Announces 2025 Interim Results
SHENZHEN, China, Aug. 27, 2025 /PRNewswire/ -- Key Highlights from the Financial Report: Revenue surged 404% year over year to...
Vaccine
Analytical Platform for Rapid, Reliable mRNA Modality Analytics, Upcoming Webinar Hosted by Xtalks
In this free webinar, gain insight into rapid, reliable analytics for evolving mRNA modalities. Attendees will learn about mRNA modality-specific CQA...
Fresenius Leads New EASYGEN Consortium Aimed at Decentralizing CAR-T Cell Therapy and Improving Hospital Workflows
Physicians, researchers, and partner institutions across Europe aim to deliver innovative, personalized therapies more quickly Development project focused on a...
BryceTech Awarded $70 Million in Prime Contracts to Advance CBRN Capabilities for the U.S. Department of Defense
ALEXANDRIA, Va., Aug. 26, 2025 /PRNewswire/ -- BryceTech has secured three multi-year prime contracts from the U.S. Department of Defense,...
BryceTech Awarded $70 Million in Prime Contracts to Advance CBRN Capabilities for the U.S. Department of Defense
ALEXANDRIA, Va., Aug. 26, 2025 /PRNewswire/ -- BryceTech has secured three multi-year prime contracts from the U.S. Department of Defense,...
Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone CAMBRIDGE, MA / ACCESS Newswire...
IgniteData Appoints Dr. David Rhew, Global Chief Medical Officer of Microsoft, to Board of Directors
NEW CASTLE, Del., Aug. 21, 2025 /PRNewswire/ -- IgniteData, a leader in intelligent clinical trial data automation, is proud to announce...
Moderna to Present at Upcoming Conferences in September 2025
CAMBRIDGE, MA / ACCESS Newswire / August 21, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced its participation in the following...
Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights
US Food and Drug Administration (FDA) has accepted the company's Type C meeting request and SKNJCT-003 Phase 2 study has...
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company...
A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
SHELTON, CONNECTICUT / ACCESS Newswire / August 18, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"),...
Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine
First-in-human trial of Capricor’s StealthX™ vaccine initiated under HHS’s Project NextGenTrial conducted and funded by the National Institute of Allergy...
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older
Saint Herblain (France), August 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced...
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business UpdatesEntered into a definitive...
Artera Flows Agents Facilitate 42M Unique Patient Sessions with 94% of Conversations Completed Without Staff Intervention
AI Virtual Agents Powering Operational Gains for 135+ Healthcare Providers Through 1,000+ Distinct Flows SANTA BARBARA, Calif., Aug. 14, 2025...
Applied DNA Reports Third Quarter Fiscal 2025 Financial Results
STONY BROOK, NY / ACCESS Newswire / August 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the...
Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Favorable CDI-988 Phase 1 safety and tolerability reported Challenge study with CDI-988 as a norovirus preventive and treatment planned later this...
Evaxion announces business update and second quarter 2025 financial results
COPENHAGEN, Denmark, August 14, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered...
Parents Urged to Make Kids’ Bedtime Screen-Free as National Campaign Launches with NYC Flash Mob
"Screen-Free Sleep" movement takes to the streets to address America's youth sleep crisis NEW YORK, Aug. 14, 2025 /PRNewswire/ --...
Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical...